IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

@article{Winblad2007IDEALA6,
  title={IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.},
  author={Bengt Winblad and George T Grossberg and Lutz Fr{\"o}lich and Martin Farlow and Stefanie Zechner and Jennifer Nagel and Roger Lane},
  journal={Neurology},
  year={2007},
  volume={69 4 Suppl 1},
  pages={
          S14-22
        }
}
The rivastigmine patch is the first transdermal treatment for Alzheimer disease (AD). By providing continuous delivery of drug into the bloodstream over 24 hours, transdermal delivery may offer benefits superior to those of oral administration. This study compared the efficacy, safety and tolerability of rivastigmine patches with capsules and placebo. IDEAL (Investigation of transDermal Exelon in ALzheimer's disease) was a 24-week, double-blind, double-dummy, placebo- and active-controlled… CONTINUE READING
Highly Cited
This paper has 151 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

151 Citations

01020'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 151 citations based on the available data.

See our FAQ for additional information.